CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.

Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.

The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.

North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.

Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.

Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.